RxDoctor Payments Data

Lowell Michael

Dermatology · Asheville, NCNPI 1942516992

Payments from drug & device makers

$1,418in general payments, 2019–2025

Across 43 payments — averaging $32.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biofrontera Inc.$501
  • Regeneron Healthcare Solutions, Inc.$298
  • Sanofi$168
  • AbbVie$123
  • Lilly USA, LLC$94
  • Galderma Laboratories, L.p.$72
  • plus $163 from 7 others

What the payments were for

  • Speaking & faculty fees$35025%
  • Food & beverage$1,06875%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biofrontera Inc.3$501
Regeneron Healthcare Solutions, Inc.11$298
Sanofi8$168
AbbVie7$123
Lilly USA, LLC4$94
Galderma Laboratories, L.p.1$72
Sun Pharmaceutical Industries Inc.3$52
Bristol Myers Squibb1$22
Dermira, Inc.1$22
Prugen, Inc. Pharmaceuticals1$22
Pfizer1$17
Amgen1$17
Promius Pharma LLC1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,418 in reported general payments places this provider in the 35th percentile of 475 dermatology providers in North Carolina.

See all dermatology providers in North Carolina

Medicare billing

Part B allowed, 2024
$290,084
Medicare patients
1,140
Services billed
4,342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast29$139,576
Clobetasol Propionate177$8,461
Ketoconazole441$6,342
Fluorouracil45$3,611
Calcipotriene25$3,279
Triamcinolone Acetonide400$3,202
Ciclopirox65$2,343
Doxycycline Hyclate70$1,994
Tacrolimus16$1,714
Fluocinonide44$1,489
Metronidazole32$1,431
Tretinoin12$1,361
Clindamycin Phosphate65$1,339
Fluconazole91$1,218
Minoxidil99$1,059

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$17$139,57629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 475 dermatology providers in North Carolina.

Other dermatology in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →